Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2013

Open Access 01-11-2013 | Clinical Trial

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

Authors: S. Ohno, L. W. C. Chow, N. Sato, N. Masuda, H. Sasano, F. Takahashi, H. Bando, H. Iwata, T. Morimoto, S. Kamigaki, T. Nakayama, S. Nakamura, K. Kuroi, K. Aogi, M. Kashiwaba, H. Yamashita, K. Hisamatsu, Y. Ito, Y. Yamamoto, T. Ueno, E. Fakhrejahani, N. Yoshida, M. Toi

Published in: Breast Cancer Research and Treatment | Issue 1/2013

Login to get access

Abstract

This randomized, multicenter study compared the efficacy of docetaxel with or without capecitabine following fluorouracil/epirubicin/cyclophosphamide (FEC) therapy in operable breast cancer and investigated the role of Ki67 as a predictive biomarker. Patients were randomized to 4 cycles of docetaxel/capecitabine (docetaxel: 75 mg/m2 on day 1; capecitabine: 1,650 mg/m2 on days 1–14 every 3 weeks) or docetaxel alone (75 mg/m2 on day 1 every 3 weeks) after completion of 4 cycles of FEC (5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2 and cyclophosphamide 500 mg/m2 on day 1 every 3 weeks). The primary endpoint was the pathological complete response (pCR) rate. Predictive factor analysis was conducted using clinicopathological markers, including hormone receptors and Ki67 labeling index (Ki67LI). A total of 477 patients were randomized; the overall response in the docetaxel/capecitabine and docetaxel groups was 88.3 and 87.4 %, respectively. There were no significant differences in the pCR rate (docetaxel/capecitabine: 23 %; docetaxel: 24 %; p = 0.748), disease-free survival, or overall survival. However, patients with mid-range Ki67LI (10–20 %) showed a trend towards improved pCR rate with docetaxel/capecitabine compared to docetaxel alone. Furthermore, multivariate logistic regression analysis showed pre-treatment Ki67LI (odds ratio 1.031; 95 % CI 1.014–1.048; p = 0.0004) to be a significant predictor of pCR in this neoadjuvant treatment setting. Docetaxel/capecitabine (after 4 cycles of FEC) did not generate significant improvement in pCR compared to docetaxel alone. However, exploratory analyses suggested that assessment of pre-treatment Ki67LI may be a useful tool in the identification of responders to preoperative docetaxel/capecitabine in early-stage breast cancer.
Appendix
Available only for authorised users
Literature
1.
Wolmark N, Wang J, Mamounas E et al (2001) Preoperative chemotherapy in patients with operable breast cancer: 9-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96–102PubMedCrossRef
2.
Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26(5):778–785PubMedCrossRef
3.
Rouzier R, Perou C, Symmans W et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685PubMedCrossRef
4.
Nolen B, Marks KJ, Ta’san S et al (2008) Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res 10:R45PubMedCrossRef
5.
Fasching PA, Heusinger K, Haeberle L et al (2011) Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11:486PubMedCrossRef
6.
Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019–2027PubMedCrossRef
7.
Toi M, Nakamura S, Kuroi K et al (2008) Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110:531–539PubMedCrossRef
8.
Sawada N, Ishikawa T, Fukase Y et al (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4:1013–1019PubMed
9.
Miwa M, Ura M, Nishida M et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281PubMedCrossRef
10.
Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493PubMed
11.
Blum JL, Dieras V, Lo Russo PM et al (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759–1768PubMedCrossRef
12.
Jinno H, Sakata M, Hayashida T et al (2010) A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer. Ann Oncol 21:1262–1266PubMedCrossRef
13.
Natoli C, Cianchetti E, Tinari N et al (2007) A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. Ann Oncol 18:1015–1020PubMedCrossRef
14.
Lebowitz PF, Eng-Wong J, Swain SM et al (2004) A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res 10:6764–6769PubMedCrossRef
15.
O’Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823PubMedCrossRef
16.
Bouzubar N, Walker KJ, Griffiths K et al (1989) Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59:943–947PubMedCrossRef
17.
Mikami Y, Ueno T, Yoshimura K, Tsuda H, Kurosimi M, Masuda S et al. (2013) Inter-observer concordance of Ki67 labeling index in breast cancer. Japan Breast Cancer Research Group (JBCRG) Ki67 Ring Study. Cancer Sci. doi:10.​1111/​cas.​12245
18.
Stefanou D, Batistatou A, Nonni A, Arkoumani E, Agnantis NJ (2004) p63 expression in benign and malignant breast lesions. Histol Histopathol 19(2):465–471PubMed
19.
Dewar R, Fadare O, Gilmore H, Gown AM (2011) Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology. Arch Pathol Lab Med 135(4):422–429PubMed
20.
Werling RW, Hwang H, Yaziji H, Gown AM (2003) Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol 27(1):82–90PubMedCrossRef
21.
von Minckwitz G, Rezai M, Loibl S et al (2010) Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro Study. J Clin Oncol 28(12):2015–2023CrossRef
22.
Leonard R, O’Shaughnessy J, Vukelja S et al (2006) Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 17:1379–1385PubMedCrossRef
23.
Caudle AS, Ganzalez-Angulo AM, Hunt KL et al (2010) Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(11):1821–1828PubMedCrossRef
24.
Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E et al (2012) Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 48(18):3342–3354PubMedCrossRef
25.
Yerushalmi R, Woods R, Ravdin PM et al (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11:174–183PubMedCrossRef
26.
Zhang GC, Qian XK, Guo ZB et al (2012) Pre-treatment hormal receptor status and Ki67 index predict pathological complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients. Med Oncol 29(5):3222–3231
27.
Luporsi E, Andre F, Spyratos F et al (2012) Ki-67: level of evidence and methodoligical considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 132(3):895–915
Metadata
Title
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy
Authors
S. Ohno
L. W. C. Chow
N. Sato
N. Masuda
H. Sasano
F. Takahashi
H. Bando
H. Iwata
T. Morimoto
S. Kamigaki
T. Nakayama
S. Nakamura
K. Kuroi
K. Aogi
M. Kashiwaba
H. Yamashita
K. Hisamatsu
Y. Ito
Y. Yamamoto
T. Ueno
E. Fakhrejahani
N. Yoshida
M. Toi
Publication date
01-11-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2691-y

Other articles of this Issue 1/2013

Breast Cancer Research and Treatment 1/2013 Go to the issue

Clinical trial

Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10 % weight loss in postmenopausal women

Epidemiology

Long-term surveillance mammography and mortality in older women with a history of early stage invasive breast cancer

Epidemiology

Validation of Rosner–Colditz breast cancer incidence model using an independent data set, the California Teachers Study

Preclinical study

Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer

Clinical trial

Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer

Epidemiology

The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits